BRÈVE publiée le 12/07/2024 à 18:07, il y a 2 mois 8 jours Funding Circle Plc : Transaction POS en actions propres Rachat D'actions Actions Ordinaires Bourse De Londres Cercle De Financement Deutsche Numis
BRÈVE publiée le 12/07/2024 à 18:07, il y a 2 mois 8 jours Funding Circle Plc: POS-Transaction in Own Shares London Stock Exchange Ordinary Shares Share Buyback Funding Circle Deutsche Numis
COMMUNIQUÉ DE PRESSE publié le 12/07/2024 à 18:02, il y a 2 mois 8 jours Funding Circle Plc: POS-Transaction in Own Shares Funding Circle Plc announces purchase of 200,000 ordinary shares for cancellation as part of buy-back program, with highest price paid at 102.50p and lowest at 98.00p London Stock Exchange Ordinary Shares Buy-back Program Cancellation Funding Circle Plc
BRÈVE publiée le 11/07/2024 à 18:27, il y a 2 mois 9 jours Funding Circle Plc exécute un rachat d'actions Rachat D'actions Actions Ordinaires Numis Securities Bourse De Londres Cercle De Financement
BRÈVE publiée le 11/07/2024 à 18:27, il y a 2 mois 9 jours Funding Circle Plc Executes Share Buyback London Stock Exchange Ordinary Shares Share Buyback Numis Securities Funding Circle
COMMUNIQUÉ DE PRESSE publié le 11/07/2024 à 18:22, il y a 2 mois 9 jours Funding Circle Plc: POS-Transaction in Own Shares Funding Circle Holdings plc purchased 284,000 of its ordinary shares for cancellation on 11 July 2024. The highest price paid per share was 100.50p London Stock Exchange Ordinary Shares Share Buyback Cancellation Funding Circle Plc
BRÈVE publiée le 10/07/2024 à 18:00, il y a 2 mois 10 jours Funding Circle Plc: Share Buyback Details London Stock Exchange Share Buyback Funding Circle Financial Transaction Stock Cancellation
BRÈVE publiée le 10/07/2024 à 18:00, il y a 2 mois 10 jours Funding Circle Plc : détails du rachat d'actions Rachat D'actions Bourse De Londres Cercle De Financement Transaction Financière Annulation De Stock
COMMUNIQUÉ DE PRESSE publié le 10/07/2024 à 17:55, il y a 2 mois 10 jours Funding Circle Plc: POS-Transaction in Own Shares Funding Circle Holdings plc announces purchase and cancellation of 201,981 ordinary shares at various prices, aiming to total 346,717,909 issued shares. No shares are in Treasury London Stock Exchange Share Buyback Stock Exchange Funding Circle Plc Share Cancellation
BRÈVE publiée le 09/07/2024 à 18:06, il y a 2 mois 11 jours Funding Circle Plc Announces Share Buyback Transaction London Stock Exchange Ordinary Shares Share Buyback Market Abuse Regulation Funding Circle
Publié le 20/09/2024 à 17:40, il y a 15 heures 49 minutes Availability of the 2024 Half-Year Financial Report
Publié le 20/09/2024 à 17:40, il y a 15 heures 49 minutes Mise à disposition du Rapport Financier Semestriel 2024
Publié le 20/09/2024 à 23:40, il y a 9 heures 49 minutes Integrated BioPharma Reports Results for Its Quarter and Fiscal Year Ended June 30, 2024
Publié le 20/09/2024 à 23:30, il y a 9 heures 59 minutes Final Bell Holdings International Ltd. Announces Sale of Final Bell Corp.
Publié le 20/09/2024 à 23:00, il y a 10 heures 29 minutes AI/ML Innovations Inc. Provides Second Status Update
Publié le 20/09/2024 à 22:30, il y a 10 heures 59 minutes Electric Metals Announces Changes to its Board of Directors
Publié le 20/09/2024 à 22:15, il y a 11 heures 14 minutes Torq Clarifies Finder’s Warrant Exercise Price of $0.10 Financing
Publié le 20/09/2024 à 22:58, il y a 10 heures 30 minutes Freelance.com: Mise à disposition du Document d’Enregistrement Universel 2023
Publié le 20/09/2024 à 21:00, il y a 12 heures 28 minutes Aurubis celebrates ribbon-cutting at the first multimetal recycling plant in the United States
Publié le 20/09/2024 à 20:14, il y a 13 heures 14 minutes EQS-Adhoc: GRAMMER AG sells TMD Group in North America
Publié le 20/09/2024 à 19:50, il y a 13 heures 38 minutes BRAIN Biotech AG concludes major pharma compound transaction valued up to EUR 128.88 million from its BioIncubator
Publié le 20/09/2024 à 19:47, il y a 13 heures 41 minutes EQS-Adhoc: BRAIN Biotech AG concludes royalty monetization deal for up to EUR 128.88 million on investigational pharma compound deucrictibant with Royalty Pharma